July 18th 2025
Take a look back through some of the top stories from the first half of the year.
GU Tumor Board: Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies
September 27, 2025
Register Now!
Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD
View More
Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment
View More
FDA accepts HIFU maker’s pre-market application
April 22nd 2013EDAP TMS said the FDA has provided a positive filing review notification on the company’s pre-market approval application for its Ablatherm Integrated Imaging HIFU (high-intensity focused ultrasound) device for the treatment of low-risk, localized prostate cancer.
PSA screening cuts prostate cancer deaths by 32%, ERSPC data indicate
April 19th 2013New evidence from the second-largest section of the European Randomized Study of Screening for Prostate Cancer (ERSPC) suggests that prostate cancer screening is beneficial, particularly in the core age group of 55 to 69 years.
Evolving algorithm for treating male voiding symptoms
April 18th 2013The algorithm for urologists’ approach to male voiding symptoms is evolving, according to Steven A. Kaplan, MD, of Weill Cornell Medical College, New York. This will be evident in presentations on BPH and lower urinary tract symptoms at the AUA annual meeting.
Diabetes, prostate cancer link: Surprising, or not?
April 17th 2013Men with abnormal findings on digital rectal exam or other indicators of prostate cancer should be tested, but the evidence is insufficient to justify preferentially screening diabetic men because they may be at a higher risk of developing clinically significant prostate cancer.
5-ARI does not affect prostate cancer mortality
April 2nd 2013Eighteen years of follow-up of the Prostate Cancer Prevention Trial (PCPT) suggests that 7 years of treatment with the 5-alpha-reductase inhibitor finasteride (Proscar) for prostate cancer prevention does not appear to affect mortality but does reduce the risk of a prostate cancer diagnosis.
Advanced prostate cancer agent efficacious regardless of age
April 2nd 2013Older men with metastatic castration-resistant prostate cancer (CRPC) derive a similar if not superior survival benefit from treatment with enzalutamide (Xtandi) as do younger men, according to a post-hoc analysis of the phase III AFFIRM trial.
Baldness raises PCa risk in African-Americans
March 26th 2013Baldness was associated with an increased risk of prostate cancer among African-American men, and risk for advanced prostate cancer increased with younger age and type of baldness, reported researchers from the University of Pennsylvania, Philadelphia.
ASTRO on proton therapy: More research needed
March 18th 2013The American Society for Radiation Oncology’s board of directors recently approved a statement regarding the use of proton beam therapy for prostate cancer, presumably due to recent reports suggesting the treatment provides little long-term benefit over traditional radiation despite its higher cost.
IPP placement post-T-shunt surgery appears efficacious
March 6th 2013Placement of an inflatable penile prosthesis (IPP) approximately 3 months after T-shunt surgery in men with acute ischemic priapism and refractory erectile dysfunction is associated with favorable outcomes at 1 year, according to data from a small series of such patients.
Endocrine disruptors linked to PCa, cryptorchidism
February 25th 2013Many synthetic chemicals, untested for their disrupting effects on the hormone system, may have significant health implications, including contributing to the development of prostate cancer in men and undescended testes in young males.